Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.
Francisco León RománBeatriz Pintado-CortDiana García-CasadoFrancisco Muñiz-GonzálezJosé Antonio López García-AsenjoCristina Díaz-RodríguezMaría Nieves Montoro-LópezMauricio Loucel-BellinoBeatriz Recio-MorenoSara Rebollo-GarridoYaiza Martínez-HernándezIvan CusacovichPublished in: RMD open (2023)
Given the speed of action, safety and efficacy profile observed for rituximab, we believe that this agent should be further investigated in clinical trials so that it could be included in the daily clinical management of this severe condition.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- clinical trial
- diffuse large b cell lymphoma
- rheumatoid arthritis
- respiratory failure
- chronic obstructive pulmonary disease
- idiopathic pulmonary fibrosis
- liver failure
- drug induced
- hodgkin lymphoma
- chronic lymphocytic leukemia
- physical activity
- early onset
- intensive care unit
- phase ii
- atomic force microscopy
- study protocol
- acute respiratory distress syndrome